Rare 'burrowing' oral cancer shows distinct genetic profile for early diagnosis

Cancer diagnosis can be challenging, and delayed diagnosis can allow cancer to progress, complicating treatment. Oral ...
Business Wire

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, today announced that the ...
Healio

FDA approves cemiplimab as adjuvant treatment for cutaneous squamous cell carcinoma

Please provide your email address to receive an email when new articles are posted on . The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at ...

Sun Pharma's Unloxcyt posts 50% response rate in skin cancer study

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally ...
Business Wire

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S.
ascopubs.org

Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial

Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311 Impaired homologous ...

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell ...

First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA ...

Corbus slips after updated trial data for cancer candidate

Corbus Pharma (CRBP) lost ~10% in the premarket on Tuesday after the Norwood, Massachusetts-based biotech announced the latest data from a Phase 1/2 trial for CRB-701 (SYS6002), its lead asset ...
Medscape

Squamous Cell Cancer Location May Be an Independent Predictor of Poor Outcomes

Despite a higher incidence of poor outcomes with squamous cell carcinoma tumors on the scalp, it was the lip and temple that emerged as highest risk after adjustments for other factors.